BioCryst Pharmaceuticals Revenue and Competitors

Location

#3233

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • BioCryst Pharmaceuticals's estimated annual revenue is currently $114M per year.(i)
  • BioCryst Pharmaceuticals received $100.0M in venture funding in February 2019.
  • BioCryst Pharmaceuticals's estimated revenue per employee is $197,969
  • BioCryst Pharmaceuticals's total funding is $1.3B.
  • BioCryst Pharmaceuticals's current valuation is $2.8B. (January 2022)

Employee Data

  • BioCryst Pharmaceuticals has 576 Employees.(i)
  • BioCryst Pharmaceuticals grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.9M8324%N/AN/A
#2
$5304.1M342202%N/AN/A
#3
$1.7M110%N/AN/A
#4
$1.4M9-61%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$2M130%N/AN/A
#7
$1.1M7-36%N/AN/A
#8
$6.2M408%N/AN/A
#9
$5.1M3314%N/AN/A
#10
$1.1M70%N/AN/A
Add Company

BioCryst Pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Founded in 1986, BioCryst has more than 50 employees and is experiencing continued growth. The Company's headquarters are located in Research Triangle Park, North Carolina and its Discovery Center of Excellence is in Birmingham, Alabama. With expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. The commitment of BioCryst remains unchanged. We continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$1.3B

Total Funding

576

Number of Employees

$114M

Revenue (est)

10%

Employee Growth %

$2.8B

Valuation

N/A

Accelerator

BioCryst Pharmaceuticals News

2022-04-20 - BioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on Thursday

EverSource Wealth Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $41,000. Janus Henderson...

2022-04-19 - Why BioCryst Stock Shot Nearly 5% Higher Today

American biotech BioCryst Pharmaceuticals (BCRX 4.74%) scored an important regulatory win across the Atlantic Ocean on Wednesday.

2022-04-13 - Why BioCryst Pharmaceuticals Stock Sank Today

Shares of BioCryst Pharmaceuticals (BCRX -2.81%) took it on the chin Monday, suffering a nearly 7% decline in value. Not for the first time...

2021-11-22 - BioCryst gets mas­sive cash in­fu­sion to the tune of $350M, thanks to old and new in­vestors

BioCryst is fill­ing its cof­fers again — this time in $350 mil­lion cash with the help of both old and new in­vestors. The Durham, NC biotech re­port­ed this morn­ing that it inked yet an­oth­er deal along­side a fa­mil­iar name — Roy­al­ty Phar­ma for $200 mil­lion. Roy­al­ty was the same com ...

2021-11-22 - BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK, RESEARCH TRIANGLE PARK, N.C. and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuti ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$107.9M5865%$26.3M
#2
$259.9M5890%N/A
#3
$35M591-1%$161M
#4
$140.2M623N/AN/A
#5
$213.3M63212%N/A

BioCryst Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2004-02-18$21.4MCommon StockArticle
2007-08-07$65.3MUndisclosedArticle
2009-11-20$56.1MUndisclosedMorgan StanleyArticle
2011-03-10$30.0MUndisclosedMorgan Stanley & Co IncorporatArticle
2013-08-01$17.6MUndisclosedWells Fargo Securities, JMP SecuritiesArticle
2014-05-29$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2016-09-27$23.0MUndisclosedMidcap FinancialArticle
2017-03-13$51.7MUndisclosedJ.P. Morgan Securities LLCArticle
2017-09-13$92.0MUndisclosedJ.P. Morgan Securities LLCArticle
2019-02-08$100.0MUndisclosedMidcap Financial TrustArticle